Sentynl

pay deal hand over cash licensing transaction money
Biotech

Zydus’ Sentynl pens $475M deal for Mereo's rare lung disease drug

Sentynl has penned a deal potentially worth $475 million for the option to market Mereo's phase 3-ready genetic respiratory disease drug in the U.S.
Marissa Russo Aug 11, 2026 10:20am
end of the road road block shut down closed blocked

FDA snubs Fortress' Zydus-partnered Menkes disease candidate

Oct 1, 2025 12:00pm